Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL.

Lancet Respir Med. 2018 Jun 8. pii: S2213-2600(18)30135-8. doi: 10.1016/S2213-2600(18)30135-8. [Epub ahead of print]

PMID:
29891356
2.

Dual functionality of β-tryptase protomers as both proteases and cofactors in the active tetramer.

Maun HR, Liu PS, Franke Y, Eigenbrot C, Forrest WF, Schwartz LB, Lazarus RA.

J Biol Chem. 2018 Jun 22;293(25):9614-9628. doi: 10.1074/jbc.M117.812016. Epub 2018 Apr 16.

PMID:
29661938
3.

Reactive-site-centric chemoproteomics identifies a distinct class of deubiquitinase enzymes.

Hewings DS, Heideker J, Ma TP, AhYoung AP, El Oualid F, Amore A, Costakes GT, Kirchhofer D, Brasher B, Pillow T, Popovych N, Maurer T, Schwerdtfeger C, Forrest WF, Yu K, Flygare J, Bogyo M, Wertz IE.

Nat Commun. 2018 Mar 21;9(1):1162. doi: 10.1038/s41467-018-03511-6.

4.

Previously reported placebo-response-associated variants do not predict patient outcomes in inflammatory disease Phase III trial placebo arms.

Haug-Baltzell A, Bhangale TR, Chang D, Dressen A, Yaspan BL, Ortmann W, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco KT, Tom JA, Cowgill A, Vogel J, Forrest WF, Behrens TW, Graham RR, Wuster A.

Genes Immun. 2018 Mar 18. doi: 10.1038/s41435-018-0018-z. [Epub ahead of print]

PMID:
29550837
5.

USP7 small-molecule inhibitors interfere with ubiquitin binding.

Kategaya L, Di Lello P, Rougé L, Pastor R, Clark KR, Drummond J, Kleinheinz T, Lin E, Upton JP, Prakash S, Heideker J, McCleland M, Ritorto MS, Alessi DR, Trost M, Bainbridge TW, Kwok MCM, Ma TP, Stiffler Z, Brasher B, Tang Y, Jaishankar P, Hearn BR, Renslo AR, Arkin MR, Cohen F, Yu K, Peale F, Gnad F, Chang MT, Klijn C, Blackwood E, Martin SE, Forrest WF, Ernst JA, Ndubaku C, Wang X, Beresini MH, Tsui V, Schwerdtfeger C, Blake RA, Murray J, Maurer T, Wertz IE.

Nature. 2017 Oct 26;550(7677):534-538. doi: 10.1038/nature24006. Epub 2017 Oct 18.

PMID:
29045385
6.

Identifying and mitigating batch effects in whole genome sequencing data.

Tom JA, Reeder J, Forrest WF, Graham RR, Hunkapiller J, Behrens TW, Bhangale TR.

BMC Bioinformatics. 2017 Jul 24;18(1):351. doi: 10.1186/s12859-017-1756-z.

7.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR.

NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016.

8.

BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats.

Weber M, Wu T, Meilandt WJ, Dominguez SL, Solanoy HO, Maloney JA, Ngu H, Baca M, Kung C, Lima L, Earr TK, Fleck D, Shields SD, Forrest WF, Foreman O, Warming S, Watts RJ, Scearce-Levie K.

Sci Rep. 2017 Mar 10;7:44249. doi: 10.1038/srep44249.

9.

Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

Ong CC, Gierke S, Pitt C, Sagolla M, Cheng CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, Campbell DA, Zheng W, Dehdashti S, Shen M, Yang N, Behnke ML, Huang W, McKew JC, Chernoff J, Forrest WF, Haverty PM, Chin SF, Rakha EA, Green AR, Ellis IO, Caldas C, O'Brien T, Friedman LS, Koeppen H, Rudolph J, Hoeflich KP.

Breast Cancer Res. 2015 Apr 23;17:59. doi: 10.1186/s13058-015-0564-5.

10.

Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.

Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, Friedman LS, Phillips HS.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14217-22. doi: 10.1073/pnas.1409653111. Epub 2014 Sep 15.

11.

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.

Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, Yan Y, Forrest WF, Wang Y, Raja R, Pilarsky C, de Jesus-Acosta A, Belvin M, Friedman LS, Merchant M, Jaffee EM, Zheng L, Koeppen H, Hoeflich KP.

J Pathol. 2014 Dec;234(4):502-13. doi: 10.1002/path.4412. Epub 2014 Oct 6.

12.

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng JH, Molina R, Kan D, De Mazière A, Klumperman J, Kasman I, Zhang Y, Dennis MS, Eastham-Anderson J, Jubb AM, Hwang O, Desai R, Schmidt M, Nannini MA, Barck KH, Carano RA, Forrest WF, Song Q, Chen DS, Naumovski L, Singh M, Ye W, Hegde PS.

J Clin Invest. 2013 Sep;123(9):3997-4009. doi: 10.1172/JCI67892. Epub 2013 Aug 15.

13.

Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling.

Phillips AH, Zhang Y, Cunningham CN, Zhou L, Forrest WF, Liu PS, Steffek M, Lee J, Tam C, Helgason E, Murray JM, Kirkpatrick DS, Fairbrother WJ, Corn JE.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11379-84. doi: 10.1073/pnas.1302407110. Epub 2013 Jun 25.

14.

Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.

McCleland ML, Adler AS, Deming L, Cosino E, Lee L, Blackwood EM, Solon M, Tao J, Li L, Shames D, Jackson E, Forrest WF, Firestein R.

Clin Cancer Res. 2013 Feb 15;19(4):773-84. doi: 10.1158/1078-0432.CCR-12-2638. Epub 2012 Dec 6.

15.

In situ validation of an intestinal stem cell signature in colorectal cancer.

Ziskin JL, Dunlap D, Yaylaoglu M, Fodor IK, Forrest WF, Patel R, Ge N, Hutchins GG, Pine JK, Quirke P, Koeppen H, Jubb AM.

Gut. 2013 Jul;62(7):1012-23. doi: 10.1136/gutjnl-2011-301195. Epub 2012 May 25.

PMID:
22637696
16.

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.

Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, Long JE, Hamilton P, McNutt A, Kasman I, Nannini MA, Reslan HB, Cao TC, Ho CC, Barck KH, Carano RA, Foreman O, Eastham-Anderson J, Jubb AM, Ferrara N, Johnson L.

J Pathol. 2012 Aug;227(4):417-30. doi: 10.1002/path.4053. Epub 2012 Jun 28.

PMID:
22611036
17.

Complementary proteomic tools for the dissection of apoptotic proteolysis events.

Pham VC, Pitti R, Anania VG, Bakalarski CE, Bustos D, Jhunjhunwala S, Phung QT, Yu K, Forrest WF, Kirkpatrick DS, Ashkenazi A, Lill JR.

J Proteome Res. 2012 May 4;11(5):2947-54. doi: 10.1021/pr300035k. Epub 2012 Mar 29.

PMID:
22432722
18.

ERK inhibition overcomes acquired resistance to MEK inhibitors.

Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.

Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8.

19.

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS.

J Clin Oncol. 2011 Dec 1;29(34):4482-90. doi: 10.1200/JCO.2010.33.8715. Epub 2011 Oct 24.

20.

A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress.

Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, Jackson PK, Belmont LD.

Cancer Res. 2010 Aug 1;70(15):6325-35. doi: 10.1158/0008-5472.CAN-10-0015. Epub 2010 Jul 20.

21.

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.

Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho CC, Cao TC, Lee CV, Nannini MA, Fuh G, Carano RA, Koeppen H, Yu RX, Forrest WF, Plowman GD, Johnson L.

Nat Biotechnol. 2010 Jun;28(6):585-93. doi: 10.1038/nbt.1640. Epub 2010 May 23.

PMID:
20495549
22.

A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS.

Cancer Cell. 2010 Apr 13;17(4):362-75. doi: 10.1016/j.ccr.2009.12.049.

23.

A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.

Yeung YA, Wu X, Reyes AE 2nd, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, Ferrara N, Lowman HB.

Cancer Res. 2010 Apr 15;70(8):3269-77. doi: 10.1158/0008-5472.CAN-09-4580. Epub 2010 Mar 30.

24.

Inferring the functional effects of mutation through clusters of mutations in homologous proteins.

Yue P, Forrest WF, Kaminker JS, Lohr S, Zhang Z, Cavet G.

Hum Mutat. 2010 Mar;31(3):264-71. doi: 10.1002/humu.21194.

PMID:
20052764
25.

Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1.

Korsisaari N, Ross J, Wu X, Kowanetz M, Pal N, Hall L, Eastham-Anderson J, Forrest WF, Van Bruggen N, Peale FV, Ferrara N.

Clin Cancer Res. 2008 Jan 1;14(1):249-58. doi: 10.1158/1078-0432.CCR-07-1552.

26.

Comment on "The consensus coding sequences of human breast and colorectal cancers".

Forrest WF, Cavet G.

Science. 2007 Sep 14;317(5844):1500; author reply 1500.

27.

Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.

Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10625-30. Epub 2007 Jun 6.

28.

Estimation of baculovirus titer based on viable cell size.

Janakiraman V, Forrest WF, Seshagiri S.

Nat Protoc. 2006;1(5):2271-6.

PMID:
17406467
29.

Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma.

Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG, Phillips HS.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3466-71. Epub 2007 Feb 20.

30.

Distinguishing cancer-associated missense mutations from common polymorphisms.

Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, Sebisanovic D, Stinson J, Forrest WF, Bazan JF, Seshagiri S, Zhang Z.

Cancer Res. 2007 Jan 15;67(2):465-73.

31.

Regulation of ERK3/MAPK6 expression by BRAF.

Hoeflich KP, Eby MT, Forrest WF, Gray DC, Tien JY, Stern HM, Murray LJ, Davis DP, Modrusan Z, Seshagiri S.

Int J Oncol. 2006 Oct;29(4):839-49.

PMID:
16964379
32.

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K.

Cancer Cell. 2006 Mar;9(3):157-73.

33.

A rapid method for estimation of baculovirus titer based on viable cell size.

Janakiraman V, Forrest WF, Chow B, Seshagiri S.

J Virol Methods. 2006 Mar;132(1-2):48-58. Epub 2005 Oct 6.

PMID:
16213601
34.

Weighting improves the "new Haseman-Elston" method.

Forrest WF.

Hum Hered. 2001;52(1):47-54.

PMID:
11359067
35.

Composite statistics for QTL mapping with moderately discordant sibling pairs.

Forrest WF, Feingold E.

Am J Hum Genet. 2000 May;66(5):1642-60. Epub 2000 Apr 7. Erratum in: Am J Hum Genet 2000 Jun;66(6):2020.

36.

Scheduling the four-day work week.

Forrest WF.

Can Hosp. 1972 Mar;49(3):63-5. No abstract available.

PMID:
5060899
37.

Selection, training and indoctrination of hospital industrial engineers.

Forrest WF.

Can Hosp. 1969 Oct;46(10):26-7. No abstract available.

PMID:
5823523
38.

The scope for industrial engineering activity in hospitals.

Forrest WF.

Can Hosp. 1967 Apr;44(4):59 passim. No abstract available.

PMID:
6041139
39.

Planning and conducting an efficient housekeeping department.

Forrest WF.

Can Hosp. 1967 Feb;44(2):42-4. No abstract available.

PMID:
6044910

Supplemental Content

Loading ...
Support Center